Compare MOBX & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOBX | MYO |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | United States |
| Employees | 46 | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 33.3M |
| IPO Year | N/A | 2017 |
| Metric | MOBX | MYO |
|---|---|---|
| Price | $2.02 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000,000.00 |
| Revenue This Year | N/A | $9.10 |
| Revenue Next Year | N/A | $13.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40814.79 |
| 52 Week Low | $0.13 | $0.61 |
| 52 Week High | $4.25 | $2.38 |
| Indicator | MOBX | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 44.52 |
| Support Level | $1.77 | $0.71 |
| Resistance Level | $3.06 | N/A |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 29.03 | 4.46 |
Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.